基于医学遗传学的阿尔茨海默病药物再利用

Medical genetics-based drug repurposing for Alzheimer's disease.

作者信息

Zhang Xiu-Zhen, Quan Yuan, Tang Guang-Yan

机构信息

School of Life Sciences, Shandong University of Technology, Zibo 255049, PR China.

Agricultural Bioinformatics Key Laboratory of Hubei Province, College of Informatics, Huazhong Agricultural University, Wuhan 430070, PR China.

出版信息

Brain Res Bull. 2015 Jan;110:26-9. doi: 10.1016/j.brainresbull.2014.11.003. Epub 2014 Nov 22.

DOI:10.1016/j.brainresbull.2014.11.003

PMID:25446738

Abstract

Alzheimer's disease (AD) is a disease that threatens the elderly. No efficient therapeutic method is currently available to combat AD. Drug repurposing has provided a new route for AD drug discovery, and medical genetics has shown potential in target-based drug repurposing. We compared AD-associated genes with approved drug targets and found that three are targeted by 23 approved drugs. Thus, these drugs may be used to treat AD according to the medical genetic information of the targets. In vitro and in vivo experiments revealed that four drugs, all of which are angiotensin-converting enzyme (ACE) inhibitors, had potential to treat AD.

摘要

阿尔茨海默病（AD）是一种威胁老年人的疾病。目前尚无有效的治疗方法来对抗AD。药物再利用为AD药物发现提供了一条新途径，医学遗传学在基于靶点的药物再利用方面显示出潜力。我们将AD相关基因与已批准的药物靶点进行比较，发现有三个靶点被23种已批准药物靶向。因此，根据这些靶点的医学遗传信息，这些药物可用于治疗AD。体外和体内实验表明，四种均为血管紧张素转换酶（ACE）抑制剂的药物具有治疗AD的潜力。